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The possibility of drug incompatibilities is a matter of serious concern 
when administering two or more therapeutic agents. This is especially true in 
the case of parenteral administration when one must be aware not only of thera-
peutic interactions but also chemical and physical reactions that might occur. 
In order to avoid incompatibilities, drug manufacturers have suggested 
that p(1renteral solutions be used immediately after reconstitution and that admix-
tures of parenteral products not be administered wherever possible (1,2). Physi-
cians have also stressed the importance in avoiding multiple drug therapy (3,4). 
In spite of these suggestions, the practice of multiple drug therapy is prevalent. 
Because of this, there has been an increase in awareness of the number of 
drug admixtures administered in the hospital. At the University of Michigan 
Hospital over two thirds of the intravenous fluids administered contained two or 
more therapeutic agents (5). Holysko and Ravin (6) report that 48% of the intra-
venous fluids contain one additive, 30% contain two additives, and 22% contain 
three or more additives. The survey taken by Patterson and Nordstrom (7) showed 
that 24% of the solutions administered intravenously contained two drugs 1 and that 
16% of the intravenous solutions contained three or more additives. 
The increased awareness of the problems in admixtures of parenterals has 
contributed to the increased use of centralized intravenous additive programs at 
various hospitals. The hospital pharmacist is now becoming more responsible for 
the preparation of intravenous admixtures (8). The need for additional information 
concerning potential interactions when admixtures of therapeutic agents for intra-
venous use are administered is evident. The lack of information includes, in 
addition to incompatibilities, areas of interest such as stability, sterility, and 
clinical effectiveness (8,9). 
This report will discuss a method to detect potential chemical interactions. 
The drugs under investigation are sodium ethacrynate (Edecrina) in combination 
with selected cardiovascular and psychotherapeLJtic agents when in admixture in 
normal saline solution. Possible therapeutic interactions and physical incom-
patibilities of these combinations will also be discussed. 
THERAPEUTIC INCOMPATIBILITIES 
The first type of incompatibi I ity to be considered is that which is con-
cerned with therapeutic interactions. This refers to an interaction that may affect 
the safety or efficacy of the resulting admixture. Included in this category are 
drug-induced interactions such as potentiation, antagonism, inhibition, and the 
production of t~xic sipe effects (10, 11). 
Ac.,;rding to D~le (10) therapeutic interactions appear to occur more 
frequently with the more lipid soluble dr~gs. This ma·y be· due to -the fact that 
lipid soluble drugs are more slowly excreted from the body. The altered response 
of the drug admixture may be the direct result of metabolism, transport, or renal 
clearance of the drug (4). 
Therefore, in order to predict any potential therapeutic interaction 
correctly, on~ must be fami I iar with the mechanism of action of the drugs involved 




in the admixture. A number of reports are available describing the mechanism 
of action of the potent diuretic, sodium ethacrynate. Published results show that 
the major site of action of sodium ethacrynate is the ascending limb of Henle 1s 
Loop (12-14). In addition, Hutcheon (14) states that sodium ethacrynate has a 
much shorter onset of action than the mercurials and the thiazide diuretics. 
The effect of sodium ethacrynate upon the excretion of electrolytes is an 
important consideration in the discussion of this drug•s mechanism of action. 
Most researchers agree that there is an increase in the excretion of sodium and 
chloride ions after administration of sodium ef'hacrynate (15-17). In the case of 
potassium ion excretion, the manufacturer•s literature suggests the possibility of 
hypokalemia occurring (18). Published reports give conflicting results con-
cerning the effect of sodium ethacrynate upon potassium levels in the body (13-18). 
The administration of sodium ethacrynate in combination with the cardio-
vascular agents presents an interesting potential therapeutic interaction. This 
involves the administration of sodium ethacrynate with the digitalis drugs, 
digoxin and digitoxin. Various authors suggest that cardiac glycosides should 
not be administered with the potassium depleting diuretics ·(18-21). This 
suggestion seems to be a valid one since potassium plays a vital role in the rnech-
an ism of action of the cardiac glycosides (22). But in the case of sodium etha-
crynate, it has not yet been definitely established if potassium depletion occurs 
as mentioned above. And in fact, various investigators have administered the 
cardiac glycosides prior to, and also concurrently with, sodium ethacrynate with-
out harmful effects (23-28). 
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Therefore, the hospital pharmacist must be aware of the potential harmful 
effect of administering therapeutic agents in admixture. A knowledge of the 
mechanism of action, side effects, and fate in the body of admixtures of-drugs 
is very important. The pharmacist, in preparing admixtures of parenl·eral 
products, should be able to predict and avoid any potential therapeutic inter-
actions. A greater awareness of these problems on the part of the hospital 
pharmacist would be of great value. Nurses and physicians would then be free 
.to perform their function in the hospital without having to cope with therapeutic 
incompatibi I ities. 
PHYSICAL INCOMPATIBILITIES 
The second type of incompatibility is that which is concerned with physical 
interactions. These are considered to be those interactions that can be observed 
wi.th the naked eye. Incompatibilities of this type manifest themselves as the 
formation of particulate matter such as a precipitate, flocculence, turbidity, 
cloudiness, color or odor change (29). 
The study of intravenous admixtures and their potential physical incom-
·patibilities is not new nor has there been a lack of research in this area of 
,_ 
~ 
interest. As early as 1955 Bogash (30) published the results of his investigation 
of the compatibilities and incompatibilities of parenteral admixtures. His method 
of study consisted of preparing mixtures of various parenteral products in selected 
intravenous solutions. 'He then observed the solution for the appearance of 
particulate matter immediately after mixing and again four hours later. If no 
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particulate matter appeared within the four hour trial period, the mixture was 
considered l·o be compatible~ 
Kirkland and his we-workers (31) determined the physical compatibilities 
of selected parenteral admixtures. The drug under consideration w~s added to 
50 milliliter portions of various infusion fluids. The concentration used was that 
of the highest dosage level generally prescribed. Changes in color as well as 
haze or precipitate formatio-n was noted immediately and at one, six and twenty-
four hour periods. It should be noted that no attempt was made to determine the 
compatibilities of two drugs in an infusion fluid. 
As is the case with several other compatibility studies, Riffkin 1s study 
·centered primarily upon the parenteral products of a single manufacturer (32). 
Unfortunately the procedqre used to determine compatibility was not published. 
He suggested that incompatibility is due to pH, viscosity, tonicity, particle size, 
oxidation, reduction, storage temperature, or exposure to I ight. 
Misgen (33) determined the physical compatibilities of 34 drugs intended 
for intravenous use. In his work one milliliter of the initial drug was injected 
into a vial containingfive milliliters of sterile distilled water. Into this solution 
was injected one mill.iliter of a solution of the combining drug and the resulting 
solution was checked immediately. A second check was made two hours later. 
If any particulate matter was observed, the combination was considered to be 
incompatible. No reference was made to the concentration of each drug used 
in this study. 
Dunsworth and Kenna (34) performed a preliminary study on the physical 
incompatibilities of selected medications. A certain concentration of each 
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therapeutic agent was added to 100 milliliters of Dextrose Injection (5%). A 
total of 24 drugs was examined and several limitations of the procedure were 
outlined. These included such things as only one concentration of the drug was . 
used and that chemical, bacteriological or physiological incompatibilities were 
not considered. 
Patel and Phillips (35) used microscopic methods to determine the phys-
drugs were prepared in selected infusion fluids. A drop of a solution was placed 
on a microscope slide and a drop of another solution was added. This mixture 
was examined under a microscope for the presence of parl'iculate matter. If a 
mixture showed the development of a precipitate, then different dilutions of the 
same drug admixture were studied in the same manner. 
As a result of the work undertaken in the area of physical incompatibilities, 
various compatibility charts have become available (36-38). These charts are 
based upon original research or are compilations of published studies on paren-
teral admixture incompatibilities. These charts usually list products frequently 
used in the hospital and indicate those mixtures which are compatible. While 
-
serving as a useful aid to the hospital pharmacist, these charts do have limi- ~ 
tations and disaavanfages. For example, any conclusion pertaining to admixture 
compatibility is based upon the detection of particulate matter. No claim is 
made concerning chemical or therapeutic incompatibility and the results are 
limited, therefore, to physical compatibility. 
Another limitation in the use of the compatibility charts concerns the 
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concentrations used in the determination of the compatibility of the admixture. 
In most cases no mention is made of the amount of drug used in the infusion fluid 
under investigation. This may lead to errors in predicting and avoiding physical 
interactions, especially in those inst.ances when· the incompatibility may be 
dependent upon the concentrations of the reactants. 
Because of the lack ot uniformity in the methods that have been used to 
detect physical incompatibility, those guides which are merely compilations of 
the work of various investigators are actually accumulations of the results of 
admixture studies based upon different methods of detection. It is important to 
... be familiar with the methods used to determine compatibility, especially if the 
methods do not simulate actual clinical practice. The validity of the results may 
be questioned if the methods bear little correlation to procedures used in medical 
treatment. 
In comparing the various published compatibility charts, one can easily 
note inconsistencies. The cause for these inconsistencies can be attributed to a 
number of variables. One such important variable is the brand of parenteral 
product used in the study. Additives such as buffers and preservatives vary from 
manufacturer to manufacturer. While these additives are considered to bethera-
peutically inert, they may be the cause of incompatibility. For this reason a 
parenteral product manufactured by one company may be compatible in admixture, 
while the corresponding parenteral product manufactured by another company may 
not. 
Another variable to be considered is the concentration of the drugs in 
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the infusion fluid. A reaction may or may not occur depending upon the concen-
tration of the reactants. For this reason, one must be aware of the concentrations 
used in the various compatibility charts. 
Different methods used to detect physical interactions introduce important 
inconsistencies in the published compatibility charts. Further, variations in the 
order of mixing and the period of storage must be considered when applying the 
findings of previous studies to prediction of compatibility in the clinical situation. 
Considering the fact that varying experimental methods have been used by different 
invesl"igators, one can gauge the complexity of the problem. 
CHEMICAL INCOMPATIBILITIES 
The third type of incompatibility manifests itself as a result of some type 
of chemical· interaction. It has been defined as any reaction or interaction that 
·does not produce a visible change in the resultant solution but that which will de-
crease the effectiveness of one or both of the additives (10). This interaction can 
be related to the acidic or basic characteristics of the drugs involved, or to oxi-
dation, reduction, hydt'olysis, or other forms of chemical reaction. 
It has been suggested that the term chemical incompatibility is a misnomer 
(39), because both a physical and a chemical. incompatibility must begin with a 
chemical reaction .. A more meaningful term would be a 11 non visuaJI• incompat-
ibility. Additional terminology suggested has been 11 soluble11 and 11 insoluble11 
I 
incompatibility (40). · These suggestions are based upon one major difference 
between the definition of physical and chemical incompatibility, which is the 











that chemical interactions are not visible because the by-produc~s of the reaction 
cil'e soluble. 
Little published information is available on chemical incompal'ibility of 
intravenous admixtures~ Perhaps, part of the reason for lack of information 
concerning this area of incompatibility is the difficulty in detecting a chemical 
reaction that does not produce a visible change in the system. As stated by 
n .I . /'1\ tl I r I • • I I • I • I • I I •• • I 
rarKer \ IJ mernoas or ana1ys1s musr oe aev1sea m wn1cn aecomposmon can oe 
detected, even in the presence of other drugs that might interfere. 
· Methods to detect chemical interactions have been based upon pH studies 
and stability studies to determine the loss of activity of the therapeutic agents. 
As defined by Schou (42) stability is that period of time when a preparation no 
longer fulfills the specifications of the Pharmacopeia or until the potency of the 
P.reparation has been reduced by more than ten per cent. ,== 
The stability of tetracycline was studied by Huang and his co-workers (43). 
They determined the stability of tetracycline in relation to pH and temperature. 
Biological tests and also change in absorbance at the wavelength of maximum 
absorbance of the drug were used to detect any loss in activity. This work was --
E 
not concerned with any admixtures but did demonstrate a method to detect the loss 
in activity of tetracycline • 
. As heat greatly affects the stability of tetracycline, Garrett (44) 
attempted to detect the end products of tetracycline after heating its solution. 
To accomplish this determination, spectrophotometric analysis was employed. 
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His results were based upon a complete ultraviolet (U.V .) scan of tetracycline 
before and after heating. The shift in the U.V. absorption maxima of tetra-
cycline after heating was consistent with the expected scan.if the tetracyclin.e 
was transformed in part to anhydrotetracycl ine. 
Gallelli (45) determined the percentage potency of selected drugs in 
different parenteral solutions. A total of six drugs in two intravenous infusion 
fluids were studied. Three drugs were assayed spectrophotometrically and three 
were assayed microbiologically. The percentage potency was determined using 
the absorbance at a specific wavelength~ and stability was determin·ed over c1 
twelve day period. 
One of the earlier studies to detect loss of activity of therapeutic agents 
in admixture was performed by Dony-·Crotteux (46). He studied the inactivation 
of antibiotics by vitamins. By the use of the growth curve method, he was able 
to determine the effect of various vitamins in solution with selected antibiotics. 
lm and Latiolais (47) determined the physico-.chemical incompatibilities 
of admixtures of penicillins and tetracyclines in Dextrose Injection, U.S. P. 
It was assumed that the incompatibility was due to the difference in pH of the -
E 
drugs. The pH of the solutions were altered and degradation due to the acidic 
and basic character was detected spectrophotometrically. The mixtures were rated 
incompatible if a loss in absorbance occurred at the wavelength of maximum ab- ' 
. . 
sorption· for each drug·. 
Parker (1) presented an interim report of a chemical compatibility study. 
Involved were some common examples of incompatibilities which do not produce 
11 
o visual change in the mixtures. Eight parenteral products in various intravenous 
fluids were examined but no mention was made of the method of testing the solu-
' tions. 
Edward (48) considered pH to be an important factor in the prediction of 
admixture instability. In that study, the pH change in an intravenous vehicle 
was determined after a drug or drugs were added. This information was then com-
pared to the known pH stability range of each drug. The results of the comparison 
were used to predict the possible acid-base stability of the drugs in a vehicle. 
Carlin and Perkins (49) discussed a rnethodto predict potential chemical 
reactions. Drugs under consideration were the penici II ins, the tetracyc I ines, 
B complex vitamins, hydrocortisone, and aminophylline. The influence of the 
acidic or basic character of the additives on their reactivity was emphasized. 
Using chemical incompatibility data, they were able to devise a method of esti-
mating the reaction rates of certain additives. This method involved calculating 
thia time required for ten per cent of the drug to react. Therefore, these authors 
calculated. the time necessary for the admixture to lose ten percent of its original 
potency. 
Similar to the work of Carlin and Perkins, is the study of Webb (40). 
He attempted to predict a pH pattern for intravenous additives. His work was 
based upon the pH and the solubility of the drugs in admixture. The degree of 
solubility is dependent upon the pH of the infusion fluid and the concentration of 
the additives. By using an appropriate equation, one can predict the pH at which 
the free acid of a soluble organic compound may begin to precipitate. 
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Parker (39) suggested the use of the pH profile as a useful tool in assessing 
chemical interactions. The pH profile is a laboratory simulation of the effect of 
pH upon a specific drug. The purpose of this profile was to identify potential 
problem areas in order that they might be avoided. The profiles were determined 
by adjusting the pH of the solutions with acid or base to simulate the addition of 
acidic or basic drugs to the test solutions. In each study a ten per cent potency 
ioss was considered significant. 
It must be noted that one should use pH values with care in predicting 
possible incompatibilities. As will be discussed later, there are several variables 
that might affect the pH stability, and therefore cause changes in the pH values. 
As can be noted from the above discussion, the available information 
concerning chemical incompatibilities of intravenous admixtures is of a limited 
nature. This lack of information may be attributed to the fact that methods <;>f 
detecting chemical interactions are difficult and usually involve indirect methods 
ofstudy. Any method that is used must include consideration of several variables. 
-These variables include the concentration of the additives, the rate of the reaction, 
the effect of the infusion fluid, pH, and the similarity of the method to actual 
~-
clinical practice. 
The purpose of this author's work is f'o devise a new method of detecting 
physiCal and chemical interactions of intravenous admixtures. This method will 
include the use of procedures that will duplicate actual clinical practice. Close 
correlation with the hospital situation will provide results that can be easily 
applied to problems associated with a centralized intravenous additive program. 
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Concentrations normally employed in clinical practice will be eval-
uated. It is likely that any chemical changes after admixture will be reflected 
in an alteration of the U.V. spectrum for each drug. The use of each of the 
;;-
drugs of an admixture pair could serve as the reference standard for evaluating 
a change in the other compound. The resu Its which fo I low appear to bear out 
the utility of this method. 
II. EXPERIMENTAL METHOD 
In an attempt to detect physical and chemical interactions of intra-
venous admixtures, sodium ethacrynate in combination with selected cardio-· 
vascular and psychotherapeutic agents were. investigated. Sodium ethacrynate 
was added to Sodium Chloride Injection, U.S. P. a, and then mixed with each 
of the following parenteral products: Hydralazine Hydrochloride (Apresolineb), 
Tolazoline Hydrochloride (Priscolineb), Reserpine (Serpasilb), Prochlorperazine 
Edisylate ( Compazinec), Chlorpromazine Hydrochloride {ThorazineC), 
Digitoxin {Crystodigind), Digoxin (Lanoxine), Procainamide Hydrochloride 
{Pronestylf), Triflupromazine Hydrochloride {Vesprinf), Promazine Hydrochloride, 
(Sparineg). 
aAbbott Laboratories, North Chicago, Ill. 
bciba Pharmaceutical Co., Summit, N.J. 
cSmith, Kline and French Laboratories 1 Philadelphia, Pa. 
.. 
dEli LillyandCo., Indianapolis, Ind. 
eBurroughs Wellcome and Co., Tuckahoe, N.Y. 
fE. R. Squibb and Sons, Div., Olin Mathieson Chemical Corp., New York, N.Y. 




U. V. absorption spectra were obtained using the Bausch and Lomb 
Spectronic 600 Double Beam Spectrophotometera. The spectra obtained were 
recorded with a Linear/Log Varicord 43 Recorderb. The solutions were mea-
sur~d in Bausch and Lomb 33-27-25 Silica Cuvettes using a dueterium lamp to 
provide an incident beam of wavelength range 200 to 350 millimicrons. 
Random dilutions in Sodium Chloride Injection, U.S. P., were made 
using volumetric flasks, graduated and measuring pipets of suitable size. 
The absorbances of these solutions were measured using sodium chloride in-
jection as the reference so I ut ion. The concentrations nec'essary to obtain 
15 
absorbance values of 0.3 to 0. 9 was established from the U.V. spectra. Beer's 
Law curves were plotted for each drug. The U.V. spectrum for each drug alone 
was considered to be the standard or theoretical results for each parenteral 
product~ 
Two problems involved in obtaining spectra for the admixture were the 
. ( 
additive effect upon the absorbance and the composite spectrum obtained as a 
result of having two drugs in solution. Therefore, in order to measure spectral 
absorbance that would be specific for an individual drug in the admixture, the 
· solution in the reference beam was changed for each measurement. The reference 
·solution contained Drug A in sodium chloride injection at the same concentration 
as was present in the Drug A + Drug B admixture. The effect of this was to obtain 
aBausch & Lomb Optical Co., Rochester, N.Y. 
bPhotovolt Corp., New York, N.Y. 
16 
a spectrum of Drug B that would resemble that ·of the standard spectrum for Drug B 
if no change in absorption or if no chemical interaction had occurred. This pro-
cedure was reversed to obtairi the spectrum fo~ Drug A in the A+ B admixture. 
ADMIXTURE ANALYSIS 
Without regard to concen_tration, direct admixture. of reconstituted sodium 
ethacrynate solution with each of the paienteial solutions under investigation \•tas 
' . 
. made. Two drops of sodium ethacrynate were mixed with two drops of the combining 
drug on a microscope slide and examined immediately for the presence of particulate 
matter. The presence of particulate matter was indicative of a physical interaction. 
Admixtures of sodium ethacrynate with each of the parenteral products 
listed above were prepared in sodium chloride injection in therapeutic concentration. 
·An admixture of therapeutic concentrations was considered to.be a therapeutic dose 
-added to 1000 milliliters of infusion fluid (See Table XI) •. When the capabilities 
of the spectrophotometer would permit, therapeutic admixtures were used to obtain 
the U. V. spectrum for each drug in the combination. As a I ready indicated, the 
reference solution used was the corresponding drug in sodium chloride injection at 
the same concentration as that of the drug in the admixture. 
In those ir1si'ances where the therapeutic concentration of the admixture 
could not be measured spectrophotometrically because of too high an absorbance, 
appropriate dilutions of the original admixture were made to obtain absorbance val-
ues within the above-mentioned range. 
All meast;rements were performed in triplicate and the pH of each solution 
17 
was obtained using the Corning Model 7 pH Metera. The U. V. spectra were ob-
tained at one, four, and eight hours after the therapeutic admixtures had been 
prepared. The results of these spectrophotometric measurements of the admixtures 
were compared with the standard spectrum of each parenteral product alone to 
detect any change in the absorption due to the added drug. 
The spectra obtained are shown in the various figures which follow. The 
admixture concentration, A max, reference solution, and the time at which the 
measurement was made are included in the legends accompanying the U.V. spectra. 
The standard spectra were obtained using the drug at the same concentration as that 
of the admixture. The changes in the pH of the admixtures Bolutions are listed in 
·the tables which follow. The values listed are averages of replicate measurements. 
The diluting solution was sodium chloride injection. 
~-
aCorning Scientific Instruments, Cambridge, Mass. 
Ill. RESULTS 
The results of the experimental findings as described in this chapter 
refer to admixtures prepared in Sodium Chloride Injection, U.S.P., at the 
concentrations indicated. These results include mean values of three replicate 
determinations. No appreciable change occurred with respect to time, and for 
this reason, no further mention of time as a variable will be made. 
Chlorpromazine Hydrochloride-Sodium Ethacrynate 
A solution containing therapeutic concentrations of sodium ethacrynate, 
50mcg./ml. and chlorpromazine hydrochloride, 50 mcg./ml., was prepared. 
To obtainoptimum results, appropriate dilutions were made to achieve a con-
centration of 40 mcg./ml. and 8mcg./ml., respectively. Neither spectrum was 
altered and the absorbance did not decrease to a significant extent during the 
eight hour study (See Fig. 1-3). These data would seem to indicate the absence 
of chemical interaction. The undiluted admixture of each drug on a microscope 
slide resulted in a cloudy solution, indicative of a physical interaction. The 
results of the pH determination are liste~ in Table I. 
TABLE I. 
Change in pH of Chlorpromazine Hydrochloride-Sodium Ethacrynate 
Admixture During Eight Hour. Period 
Solution pH 
1 Hour 4 Hours 8 Hours-
Sodium Ethacrynate, 50mcg ./rn!. 
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The absorption spectrum of sodium ethacrynate in the presence of digi-
toxin was obtained using therapeutic concentrations of each, 50mcg./ml. and 
0.2mcg ./mi., respectively. To obt?in an optimum measurement for digitoxin, 
a solution containing 20mcg./ml. of digitoxin and 50mcg./ml. of sodium 
ethacrynate was prepared. !he spectrum for sodium ethacrynate was not altered 
exhibited a loss in absorbance qt the A max in comparison to that of digitoxin 
alone (See Fig. 4-6). The loss in absorbance indicates a decrease in the con-
centration of digitoxin of approximately 40 per cent and was great enough to 
suggest a chemical interaction. Undiluted admixture of these two drugs on a 
microscope slide resulted in a clear solution, indicative of a physical compati-
biiity. The results of the pH determination are listed in Table II. 
TABLE II 
Change in pH of Digitoxin-Sodium Ethacrynate Admixture 
During Eight Hour Period 
Solution 
Sodium Ethacrynate, 50mcg ./mi. 
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Undiluted admixture of sodium ethacrynate and digoxin resulted in a 
clear solution, indicative of a physico~ compatibility 1 while the spectre-
photometric measurements of the admixture at therapeutic concentrations 
provided results suggestive of a chemical interaction. The absorption spectrum 
of sodium ethacrynate in tbe presence of digoxin was obtained using therapeutic 
concentrations of each, 50mcg./ml., and lmcg./mi., respectiveiy. To ob-
tain optimum absorbance for digoxin, a solution containing 40mcg./ml. of 
each parentera I product was prepared. The spectrum for sodium ethacrynate 
was not altered appreciably throughout the eight hour study (See Fig. 7-9), 
while that of digoxin exhibited a loss in absorbance at the ).. max in compar-
ison to that of the digoxin reference (See Fig. 7-9). From the Beer•s Law 
~ata, this loss amounted to approximately 40 per cent decrease in concen-
tration, and was significant enough to suggest a chemical interaction. The 
· results of the pH determination are listed in Table Ill. 
TABLE Ill 
Change in pH of Digoxin-Sodium Ethacrynate Admixture 
During Eight Hour Period 
Solution pH 
1 Hour 4 Hours 
Sodium Ethacrynate, 50mcg ./mi. 5.6 5.0 
Digoxin, 1mcg./ml. 3.3 3.5 
Therapeutic Admixture 6. 1 6.2 
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Hydralazine Hydrochloride-Sodium Ethacrynate 
Preparation of an admixture of therapeutic· concentration of sodium etha-. 
crynate and hydralazine hydrochloride with subsequent spectrophotometric 
measurement indicated a chemical interaction. Undiluted admixture resulted 
in a clear solution, indicative of a physica1 compatibility. Sodium ethacry-
nate and hydralazine hydrochloride were mixed in therapeutic concentrations, 
50mcg ./m!. and 20mcg ./m!., respectively. The limitations of the spectre= 
photometer prevented using this solution directly and, therefore, appropriate 
dilutions were made to achieve the optimum concentration of 40mcg ./mi. and 
16mcg./ml., respectively. The absorption spectrum obtained for sodium etha-
crynate in the admixture did not resemble the reference spectrum (See Fig. 10-
12). This is indicative of a change in the chemical nature of the additives 
and may be due to a chemical interaction. The results of the pH determination 
are listed in Table IV. 
TABLE IV 
Change in pH of Hydralazine Hydrochloride-Sodium Ethacrynate 
Admixture During Eight Hour Period 
Solution 
Sodium Ethacrynate, 50mcg ./mi. 




1 Hour 4 Hours 8 Hours 
~5~.6~--~5.~0-----~ 
5.0 4.7 4.8 
6.1 6.2 5.8 
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Procainamide Hydrochloride-Sodium Ethacrynate 
The therapeutic concentration for sodium ethacrynate and procainamide 
hydrochloride are 50mcg./ml. and lOOOmcg./ml., respectively. The capa-
bilities of the spectrophotometer prevented the use of this concentration for 
the procainamide hydrochloride determination, and therefore; appropriate 
dilutions were made to achieve an optimum concentration of 8mcg./ml. The 
spectrum showed a decrease in the absorbance at the >.max for sodium etha-
crynate (See Fig. 13-15), and some loss in the absorbance was also noted 
for .the spectrum of procainamide hydrochloride. The decrease indicates a 
loss in concentration and is suggestive of a chemical interaction. On the other 
hand, direct undiluted admixture of two drops of each parenteral product re-
suited in a clear solution, suggestive of an absence of physical interaction . 
. The results of the pH determination are listed in Table V. 
TABLE V 
Change in pH of Procainamide Hydrochloride-Sodium Ethacrynate 
Admixture During Eight Hour Period 
Solution pH 
39 
1 Hour 4 Hours 8 Hours .. ····-· 
Sodium Ethacrynate, 50mcg./ml. . 
Procainamide Hydrochloride, 1000mcg./tttl. 
Therapeutic Admixture 
Dilution 
-5-.6----5-. 0---5·. 0 :' 
5.3 5.2 5.0 
5.8 6.1 5.8 
5.8 5.9 5.9 
\ 
40 
1.8 ____________ _:_ ____ ·-~----- -~-
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Prochlorperazine Edisylate-Sodium Ethacrynate 
Sodium ethacrynate and prochlorperazine edisylate were mixed in thera-
peutic concentration, 80mcg./ml., and 20mcg ./mi., respectively. Appro-
priate dilutions were performed to achi.eve the optimum concentration of 
sodium ethacrynate, 40mcg./ml., and prochlorperazine edisylate, lOmcg./ml. 
The absorption spectrum obtained for each drug in the admixture duplicate.d the 
re ~erence spectrum expected-(See Fig:-r6~ta)-. -some ioss in absorbance was 
detected, but the loss was not significant and no appreciable loss in concen-
tration occurred. Undiluted admixture of these two drugs resu I ted in a cloudy 
solution, indicative of a physical incompatibility, while admixture at thera-
peutic concentration produced no visible change in the solution and therefore, 
no physical incompatibility can be reported. The results of the pH determin-
ation are listed in Table VI. 
TABLE VI 
·Change .in pH of Prochlorperazine Edisylate-Sodium Ethacrynate 
Admixture During Eight Hour Period 
Solution pH 
1 Hour 4 Hours 8 Hours 
Sodium Ethacrynate, 50mcg ./mi. 5.6 5.0 5.0 
Prochlorperazine Edisylate, 20mcg./ml. 6.0 5.7 5.7 
Therapeutic Admixture 6.3 6.3 6.3 
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Promazine Hydrochloride-Sodium Ethacrynate 
The therapeutic concentrations of sodium ethacrxnate, 50mcg./ml., and 
..... 
promazine hydrochloride, 50mcg./ml., were appropriately diluted to obtain 
a concentration of 40mcg ./mi., and 8mcg ./mi., respectively. The absorption 
spectrum of each was not altered to any significant extent, but some loss in 
the absorbance at the A max did occur (See Fig. 19-21). This loss in absorbance 
action. No particulate matter was observed in the admixture at therapeutic 
concentrations, but direct, undiluted admixture resulted in the formation of a 
cloudy solution. The results of the pH determination are listed in Table VII. 
TABLE VII 
Change in pH of Prochlorperazine Edisylate-Sodium Ethacrynate 
Admixture During Eight Hour Period 
Solution' 
Sodium Ethacrynate, 50mcg ./mi. 




1 Hour 4 Hours 8 Hours 
5.6 5.0 5~0 
6.2 6.4 6.5 
6.4 6.3 6.2 
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Reserpine-Sodium Ethacrynate 
An admixture was prepared using 50mcg./ml. of sodium ethacrynate 
and 20mcg./ml. of reserpine. The solution turned cloudy, indicative of 
physical evidence of a chemical reaction. Undiluted admixture of each drug 
also produced a cloudy solution. This particulate matter prevented the use 
of spectrophotometric measurements to determine the effect of this interaction 
on the absorption spectra. The resu Its of the pH determination are I isted in 
Table VIII.· 
TABLE VIII 
Change in pH of Reserpine-Sodium Ethacrynate 
Admixture During Eight Hour Period 
Solution 
Sodium Ethacrynate, 50mcg./ml. 
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Tolazol ine Hydrochloride-Sodium Ethacrynate 
A clear solution resulted when sodium ethacrynate and tolazoline hydro-
chloride were mixed undiluted on a microscope slide. This observation would 
indicate a physical compatibility. Sodium ethacrynate was used in therapeutic 
concentration, 50mcg./ml., while that of tolazoline hydrochloride was the 
optimum concentration of 400mcg./ml. This admixture also resulted in a clear 
solution. The absorption spectrum of each of these drugs in the admixture was 
altered and the presence of secondary peaks was evident (See Fig. 22-24). 
This is indicative of a change in the chemical nature of the admixture. However, 
it must be noted that tolazoline hydrochloride was present in a concentration that 
.is eight times the therapeuHc concentration. The results of the pH determination 
are listed in Table IX. 
TABLE IX 
Change in pH of Tolazol ine Hydrochloride-Sodium Ethacrynate 
Admixture During Eight Hour Period 
Solution 
Sodium Ethacrynate, 50mcg./ml. 
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Triflupromazine Hydrochloride-Sodium Ethacrynate 
Admixtures of sodium ethacrynate and triflupromazine hydrochloride, 
50mcg./ml., and 5mcg./ml., respectively, caused the production of gas in 
the solution. This would indicate physical evidence of a chemical reaction, 
and prevented the use of spectrophotometric measurement of the admixture to 
determine any chemical interaction. Undiluted admixture of these two drugs 
resuitedln a cloudy solUTion whicl101so suggests a physical interaction. The 
results of the pH determinations are listed in Table X. 
TABLE X 
Change in pH of Triflupromazine Hydrochloride-Sodium Ethacrynate 
Admixture During Eight Hour Period 
-· -----
Solution 
Sodium Ethacrynate, 50mcg./ml. 
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RESULTS OF U. V. SPECTROPHOTOMETRIC EXAMINATION OF ADMIXTURE 
Admixture Concentration {meg .iml. ~ 
· Therapeutic Scanned 
Absorbance2 ..\ max3 Spectrum4 
Sodium Ethacrynate 50 40 .55 280 no change 
Chlorpromazine HCI 50 8 .79 255 no change 
Sodium Ethacrynate 50 50 .7 280 no change 
Digitoxin 0.2 20 . 41 222 altered 
Sodium Ethacrynate 50 50 .7 280 no change 
· Digoxin 1 40 .79 220 altered 
Sod.ium Ethacrynate 50 40 .55 280 altered 
Hydralazine HCI 20 16 .87 241 altered 
Sodium Ethacrynate 50 50 .7 280 altered 
Procainamide HCI 1000 8 . 51 280 no change 
Sodium Ethacrynate 80 40 .55 280 no change 
Prochlorperazine Ed. 20 10 .86 256 no change 
Sodium Ethacrynate 50 40 .55 280 no change 
Promazine HCI 50 8 .8 253 no change 
Sodium Ethacrynate 50 50 .7 280 
Reserpine 20 20 .74 264 
Sodium Ethacrynate 50 50 .7 280 altered 
Tolazol ine HCI 400 400 .46 257 altered 
Sodium Ethacrynate 50 50 .7 280 
Triflupromazine HCI 5 5 .45 256 
1Appropriate dilutions were performed using the solutions containing the parenter~l 
produCts in therapeutic concentrations to achieve the values listed which are 
optimum concentrations. 
2The absorbance values listed are the theoretical or standard values obtained by 
· measuring each parenteral product alone in Sodium Chloride Injection, U.S.P. 
3The >..max values listed are the theoretical or standard values obtained by measur-
ing each parenteral pro~uct alone in SodiumChloride Injection, U.S. P. 
4The spectrum referred to is that measuring each parenteral product in admixture 
at the concentration I isted. Two admixtures could not be measured spectrophoto-





RESULTS OF VISUAL EXAMINATION OF ADMIXTURES 
Admixture 1. Results 
Undilutei Therapeutic3 
Chlorpromazine HCI Cloudy Clear 
Digitoxin Clear Clear -
Digoxin Clear Clear 
+-----~H¥dwJa:z:ine_!:LCI __________ __,clear _______ __.C!ear _______ _ 
Procainamide HCI Clear Clear 
Prochlorperazine Ed Cloudy Clear 
Promazine HCI Cloudy Clear 
Reserpine Cloudy Cloudy 
Tolazoline HCI Clear Clear 
Triflupromazine HCI Cloudy Evolution 
of Gas 
lEach parenteral product wa_s mixed with Sodium Ethacrynate. 
2Two drops of reconstituted Sodium Ethacrynate was mixed with two drops of 
each of the parenteral products on a microscope slide and examined immed-
iately for physic.al evidence of an interaction. 
3 A therapeutic admixture of each parentera I product with Sodium Ethacrynate 
was made in Sodium Chloride Injection, U.S.P., and examined at one, four, 
and eight hours after preparation for physical evidence of an interaction. 
Any reactions that occurred were evident within one hour after the admixture 
was prepared. 
IV. DISCUSSION 
Any method to detect chemical interactions of intravenous admixtures 
must consider several variables that may ·affect the results. As indicated 
( 
earlier, the pH of the infusion fluid 'is of extreme importance. Acid-base 
reactions are the cause of a great number of incompatibilities of therapeutic 
agents in solution, and for this reason the pH stability range of a given drug 
must be considered when preparing admixtures of parenteral products. 
The infusion vehicle can be considered to b~ an important determinant 
in the final pH of the solution. An examination of the acceptable pH ranges 
. as recognized by the compendia show wide variance. In the case of Sodium 
Chloride Injection, U.S.P., a pH range of 4.5 to 7.0 is permissible (50). 
Because of this wide range, it is possible that a drug may be compatible in one 
lot of an infusion fluid but not in another. In the case of the sodium chloride 
injection used for this study, some variation in pH was noted. The pH range 
for this vehicle from a single lot of this infusion fluid was 5.1 to 6.8, which is 
within the allowable range. 
Another factor that contributes to the pH of the admixture solution is 
the concentration and chemical nature of the additives. The effects of salts . 
of strong acids and weak bases and salts of weak acids and strong bases are 
evident, and the concentration of these salts will, of course, affect the final 
pH. Agents tho~ are present in sma II amounts have I ittle effect upon the over-




can be considered to be due to the vehicle itself. 
The .exposure of the parenteral products to atmospheric conditions greatly 
affects their pH. The dissolved gas content in the parenteral products is con-
trolled until an admixture is prepared, or until the solution is used. Once the 
solution is exposed to oxygen and carbon dioxide, the pH of the solution can 
and will change. 
For example, for a single Abbo-1 itera container of sodium chloride in-
jection, a change in pH from 6.8 to 6.2 was noted during an eight hour period. 
This infusion vehicle was exposed to the typical clinical procedure of removing 
portions of the solution using a Venopak Disposable Venoclysis Set #4622a. 
Although this may not have been a significant change in the pH, it may be of 
importance in assessing the results obtained. This is especially true in the case 
of drugs which have a narrow range of pH stability. 
The concentration of the additives and the rate of the reaction are also 
of prime importance in assessing the results obtained from the experimental method. 
If the rate of the reaction is dependent upon the concentration of the additives, 
orie must consider the effect of any dilufions that were performed~ In the spectre-· 
photometric procedure used, every effort was made to limit the admixture tech-
niques to therapeutic concentrations. In certain instances the I imitations of the 
spectrophotometer prevented this and appropriate dilutions were made in order to 
achieve optimum continuous absorbance spectra. It is possible that in diluting 
the admixture, some chemical interaction that might have occurred may have 
a . Abbott Laborator1es, North Chicago, Ill. 
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been eliminated if the reaction were concentration dependent. 
The application of the method to actual hospital conditions is also an 
important factor in assessing the results ofthe study. It is desirable to have the 
method simulate the clinical situation. Every effort was made to duplicate the· 
conditions found in a centralized intravenous additive program. Abbo-liter 
containers of the infusion solutions were used with Venopak Disposable Vena-
clysis Sets to transfer the infusion fluids. Pipets of suitable size were used to 
prepare the various dilutions. 
In obtaining the continuous U. V. absorption spectra for the admixtures, 
the need for using optimum concentrations cannot be overemphasized. This fact 
is.quite important since the reference solution contained a parenteral product in 
sodium ch Iori de injection. T~e effect of this was manifested by the occurrence of 
concentration depen_dent "noise" in the spectra obtained for certain admixtures. 
In spite of this 1 every effort was made to use therapeutic concentrations of each 
additive in order to simulate actual clinical conditions. 
In assessing the data obtained, the results were discussed in terms of 
chemical interaction. A substantial decrease in the absorbance at the wavelength 
of maximum absorbance (>-.max) would suggest a loss in concentration of the drug 
and, therefore, may be suggestive of a chemical interaction. An alteration in 
the continuous U. V. abosrption spectrum, such as the appearance of secondary 
peaks as compared to that of the spectrum of each parenteral product alone, would 
also suggest the presence of a chemical interaction; 




the various types of parenteral admixture interactions. As indicated in Chapter I, 
it has been suggested by several authors that the words "physical" and 11 chemical," 
when used to classify the types of incompatibilities, are a misnomer. This author ! 
is in agreement, for it is quite evid~nt that any interacl'ion involving two chemical 
entities is a "chemical interaction." A physical interaction (or incompal'ibility) 
is merely physical evidence_ of a chemical reaction. 
iJ---~~~~~~~---r-ermi-rn:rl-o-gy-has-bet:n--soggested-to-replace-the-ielatively-meaningless:----~~~~~~-
words, 11 physical" and 11 chemical. •• These suggestions include 11 visual 11 and 11 non-
visual" incompatibility, and also 11 soluble11 and 11 insoluble" incompatibility. 
Indeed, it appears that the incompatibilities have been classified on the basis of 
the solubility of the end products of the reaction and not upon the types of reaction 
involved. If the reaction produces a visible change in the solution, it is considered 
to be a "physical 11 incompatibility. If a reaction occurs with no particulate matter 
produced, it is considered to be a 11 che111ical 11 incompatibility. However, in 
actuality, the correct interpretation might be physical evidence or the lack of 
physical evidence of a chemical reaction. 
V. SUMMARY AND CO NCLUSJON 
The purpose of this study was to devise a method of detecting chem-
ical interactions of intravenous admixtures. Ultraviolet spectra of the drugs 
in combination were obtained. The spectra were examined for any loss in ab-
sorbance at l'he >.max, and also for any alteration in the spectra in the range 
of 200<~25 mill.imicrons. Appreciable loss in absorbance at the A. max would 
suggest a loss in the concentration of the drug and therefore, would tend to in-
dicate a chemical interaction. The appearance of a secondary ). max would be 
suggestive of an alteration in the chemical nature of the drug, and therefore, 
.would also indicate a chemical interaction. 
In the investigation of sodium ethacrynate in combination with the 
selected cardiovascular and psychotherapeutic agents, two parenteral products 
resulted in visible evidence of an interaction. Admixture with reserpine re-
sulted in a cloudy solution, while in the admixture with triflupromazine hydro-" 
chloride, the evolution of a gas was noted. These two admixtures demonstrate 
physical evidence of a chemical intera~tion. 
The admixture of sodium ethacrynate with chlorpromazine hydrochloride, 
prochlorperazine edisylate, and promazine hydrochloride, gave no evidence 
of an interaction. The admixture of therapeutic concentration did not produce 
any physical evidence of an interaction. The spectrum for each drug in the ad-
mixture was not appreciably altered throughout the eight hour study. 
Three admixtures with sodium ethacrynate exhibited a loss in absorbance 
70 
at the wavelength of maximum absorbance: digitoxin, digoxin, and procain-
amide hydrochloride. This loss may be considered to be suggestive of a 
decrease in the concentration of the additives. 
A pronounced alteration in the spectra occurred with sodium ethacry-
·nate when mixed with hydralazine hydrochloride and also with tolazoline hydro-
chloride. This change is indicative of a change in the chemical identity of the 
drug and is suggestive of a chemical interaction. 
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